Mark Lackner - Feb 1, 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Scientific Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Mark Lackner
Stock symbol
ZNTL
Transactions as of
Feb 1, 2024
Transactions value $
-$18,291
Form type
4
Date filed
2/5/2024, 07:15 PM
Previous filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +141K +250.39% $0.00 197K Feb 1, 2024 Direct F1
transaction ZNTL Common Stock Sale -$18.3K -1.59K -0.8% $11.54 196K Feb 2, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +141K $0.00 141K Feb 1, 2024 Common Stock 141K $11.69 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Scientific Officer, a role to which he was promoted on December 31, 2023.